TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05510622

Intervention type: OTHER
Intervention: Vaginal swab and endometrial biopsy
Description: A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.

Intervention type: OTHER
Intervention: Vaginal swab and endometrial biopsy
Description: A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
Study: NCT04582669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Triamcinolone 10 mg/mL
Description: Injection of 1 mL intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 20 mg/mL
Description: Injection of 1 mL intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 40 mg/mL
Description: Injection of 1 mL intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
Study: NCT06511518

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioural therapy (CBT) is a therapy that can help you manage your problems by changing the way you think and behave.
Study: NCT01586429

Intervention type: OTHER
Intervention: Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)

Intervention type: OTHER
Intervention: Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)
Study: NCT04156347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Episcleral Topotecan
Description: Transscleral Topotecan
Study: NCT05503693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 50 μg
Description: AP303 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 150 μg
Description: AP303 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 300 μg
Description: AP303 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 600 μg
Description: AP303 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 50 μg
Description: Placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 150 μg
Description: Placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300 μg
Description: Placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 600 μg
Description: Placebo tablet
Study: NCT05429099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Surgical Planning (VSP)
Description: The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free-Hand Surgery
Description: The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
Study: NCT04607681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDUCATION
Description: WEB BASED EDUCATION
Study: NCT05079321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydra-PEG
Description: Zen™ RC scleral lenses (Hydra-PEG coated)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Uncoated
Description: Zen™ RC scleral lenses (non-coated)
Study: NCT05954936

Intervention type: OTHER
Intervention: Risk factor
Description: No therapeutic or diagnostic intervention will be provided; it is an observational study.

Intervention type: OTHER
Intervention: Risk factor
Description: No therapeutic or diagnostic intervention will be provided; it is an observational study.
Study: NCT06308588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given by Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Given by PO
Study: NCT05103436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: Electrical nerve stimulation
Study: NCT06516874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)
Description: This TF-CBT-CP is a short-term intervention to treat outpatients. This will be carried out via videoconference.

Intervention type: OTHER
Group type: OTHER
Intervention: TAU
Description: waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions.
Study: NCT05166850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PICHA7 mHealth program
Description: The PICHA7 mHealth program is first delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After health facility delivery of the program, patient households receive weekly voice and text messages from the PICHA7 mHealth program over 12 months on the recommended WASH behaviors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Arm
Description: Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arm
Description: Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
Study: NCT04991350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal ranibizumab
Description: Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab
Description: Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
Study: NCT05111509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT-α-NET
Description: 3 to 5 miliCuries of \[203\]Pb administered intravenously 60 minutes before the start of the scans.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: Scans are administered over 3 days: 1 hour post injection, 4 to 8 hours post-injection, 24 to 30 hours post-injection, and 42 to 52 hours post-injection.
Study: NCT05112757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application use
Description: Use of a smartphone application
Study: NCT04991038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISe Device
Description: Thrombectomy using the DAISE device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo or Solitaire
Description: Thrombectomy using TREVO or Solitaire device
Study: NCT05347745

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: therascreen® KRAS RGQ PCR Kit
Description: Utilize a Clinical Trial Assay, the KRAS Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190172) in order to identify patients with CRC with KRAS G12C mutation positive tumors This will allow the clinical data from the study to be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.
Study: NCT06415396

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Therapy
Description: conventional CDT program consisting of MLD, compression bandage, skin care and lymphedema exercises, for a total of 15 sessions, five days a week for three weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Therapy
Description: conventional CDT program consisting of MLD, compression bandage, skin care and lymphedema exercises, for a total of 15 sessions, five days a week for three weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Therapy
Description: conventional CDT program consisting of MLD, compression bandage, skin care and lymphedema exercises, for a total of 15 sessions, five days a week for three weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: ESWT was applied to the second group for a total of 5 sessions, 2 sessions in the first two weeks and 1 session in the last week. .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT
Description: In the third group, LLLT was applied for a total of 9 sessions, 3 sessions per week, in addition to conventional CDT.
Study: NCT05532020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR (diazoxide choline) extended-release tablets
Description: All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.
Study: NCT06050291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) Tablet
Description: Obicetrapib/Ezetimibe FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) Tablet
Description: Obicetrapib/Ezetimibe FDC tablet
Study: NCT04912622

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Trial
Description: Retinal image acquisition with Cellularis version 2.0

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Trial
Description: Retinal image acquisition with Cellularis version 2.0
Study: NCT05774028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
Description: P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
Study: NCT06720168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erythritol air polisher
Description: Dental prophylaxis with erythritol air polisher in patients with dental black stain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis with ultrasonic treatment
Description: Dental prophylaxis with ultrasonic treatment in patients with dental black stain
Study: NCT06740669

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality glasses (VR) application
Description: It will be evaluated at 1 and 6 hours after the Caesarean section and a relaxing video called Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ, a video containing nature scenes accompanied by nature sounds) will be shown for a maximum of 20 minutes through virtual reality glasses (Toker and Gökduman Keleş, 2024).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Those who are applied expressive touch
Description: Expressive touch does not require any preparation other than warming the hands to the same temperature as the body temperature. During expressive touch practice; the parts of the body that are touched the most are the hands, arms, forehead, hair and shoulders. The hands are massaged during the touch and the arms and shoulders are lightly touched before and after the massage, so that the expressive touch made on the hands is effective (Pinar and Demirel, 2021; Routasalo, 1999) After the evaluation, the researcher will apply expressive touch to one of the mother's hands for an average of 15-20 minutes
Study: NCT06213519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Oxaliplatin sintilimab HIPEC
Description: 1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity.
Study: NCT04169451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
Study: NCT05483114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers
Description: The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers
Description: The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
Study: NCT01151514

Intervention type: OTHER
Intervention: Nephrologist referral
Description: Nephrologist specialty, renal replacement therapy

Intervention type: OTHER
Intervention: Nephrologist referral
Description: Nephrologist specialty, renal replacement therapy
Study: NCT05278494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: PO
Study: NCT05175300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthesis with CoPXE couple.
Description: Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis with CoC torque.
Description: Prosthesis with ceramic-on-ceramic (CoC) torque.
Study: NCT04913623

Intervention type: PROCEDURE
Intervention: Hip Replacement
Description: The hip replacement surgery is when a damaged hip is replaced with artificial one

Intervention type: PROCEDURE
Intervention: Hip Replacement
Description: The hip replacement surgery is when a damaged hip is replaced with artificial one
Study: NCT06035185

Intervention type: PROCEDURE
Intervention: apical shaping size
Description: 24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.

Intervention type: PROCEDURE
Intervention: apical shaping size
Description: 24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.
Study: NCT05234775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: 300 mg of each drug given SC as single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lerodalcibep
Description: 300 mg of each drug given SC as single dose
Study: NCT06386198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Advocate
Description: The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
Study: NCT05612841

Intervention type: OTHER
Intervention: data collection
Description: data collection from drug-drug interaction between anti-cancer treatment and and other medications

Intervention type: OTHER
Intervention: data collection
Description: data collection from drug-drug interaction between anti-cancer treatment and and other medications
Study: NCT05278494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO
Study: NCT04471571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin infiltration and microabrasion for MIH-affected incisors
Description: MIH-affected incisors will be treated with microabrasion followed by resin infiltration as a combined treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration for MIH-affected incisors
Description: MIH-affected incisors will be treated with resin infiltration alone
Study: NCT06740669

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focus
Description: . The researcher mother will be asked to focus on her baby for 10 minutes (Kiliçli Id and Zeyneloglu Id, 2024; Vamour et al., 2019).
Study: NCT06480435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physical Therapy
Description: Chest Percussion is a conventional method to clear airway and mobilize the thick mucus from the chest wall. Percussion can be applied by both manually and mechanically, but the mechanical percussion is more useful

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lungs squeezing technique
Description: It improves the oxygen saturation and lung volumes better than percussion.~This technique has two phases:~1. Squeezing phase~2. Release phase
Study: NCT06301971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral solution/suspension
Study: NCT05297110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atherolive
Description: In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atherolive
Description: In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Study: NCT05999656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human cord blood-derived mononuclear cells (HCB-MNCs)
Description: All patients received cell therapy for the first time. HCB-MNCs were injected subcutaneously or intramuscularly into the ulcers of the patients' feet, with an interval of about a centimeter between every two points and an injection volume of 0.2ml at each puncture point. The total injection volume required by the patients was the injection needles multiply 0.2ml (about 2ml of suspended cell in total). The remaining suspension was injected on both sides of the center of the main ischemic site. All patients received three injections of umbilical cord blood mononuclear cells at a week interval, with the latter two injections located around the site of the first injection. The adjuvant therapy remained unchanged within two weeks after cell injection. The follow-up period is 12 weeks after treatment to observe safety and efficacy. If the patient does not recover after 12 weeks, the follow-up period can be extended to 24 weeks.
Study: NCT06195475

Intervention type: OTHER
Intervention: high vs low tidal volume
Description: The clinical investigation aims to determine whether exposure to tidal volumes greater than 8 ml/kg of predicted body weight during the initial 72 hours of pressure support mode mechanical ventilation is associated with an increased risk of mortality in the intensive care unit when compared to individuals who maintain a tidal volume equal to or less than 8 ml/kg of predicted body weight.

Intervention type: OTHER
Intervention: high vs low tidal volume
Description: The clinical investigation aims to determine whether exposure to tidal volumes greater than 8 ml/kg of predicted body weight during the initial 72 hours of pressure support mode mechanical ventilation is associated with an increased risk of mortality in the intensive care unit when compared to individuals who maintain a tidal volume equal to or less than 8 ml/kg of predicted body weight.